Compare Neurocrine Biosciences Inc (NBIX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Vanguard Total International Stock Index Fund ETF trades at $84.62 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 46.4× Neurocrine Biosciences Inc's market cap, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| NBIX | VXUS | |
|---|---|---|
Market Cap | $14.36B | $665.70B |
Volume | 1,237,180 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $185.50 | $88.41 |
52-Week Low | $123.10 | $72.17 |
Typical Hold Time | 23 Days | 55 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
VXUS trades at $84.78, down 1.19% with a bearish technical signal from moving averages. The ETF provides broad international stock exposure outside the U.S., with institutional buying interest noted in recent SEC filings. Technical indicators show neutral oscillators but bearish momentum signals from ADX readings.
The fund offers diversification benefits as a core international holding, though recent performance faces headwinds. Key risks include currency fluctuations and emerging market volatility. Long-term outlook remains positive for global equity exposure, supported by Vanguard's low-cost structure and comprehensive market coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
